Zur Kurzanzeige

2011-05-11Zeitschriftenartikel DOI: 10.1128/​CVI.05021-11
Molecular analysis of varicella vaccines and varicella-zoster virus from vaccine-related skin lesions.
dc.contributor.authorThiele, Sonja
dc.contributor.authorBorschewski, Aljona
dc.contributor.authorKüchler, Judit
dc.contributor.authorBieberbach, Marc
dc.contributor.authorVoigt, Sebastian
dc.contributor.authorEhlers, Bernhard
dc.date.accessioned2018-05-07T14:59:55Z
dc.date.available2018-05-07T14:59:55Z
dc.date.created2011-11-18
dc.date.issued2011-05-11none
dc.identifier.otherhttp://edoc.rki.de/oa/articles/reRf4FhMksVMA/PDF/28G6yGS1yUX9g.pdf
dc.identifier.urihttp://edoc.rki.de/176904/1003
dc.description.abstractTo prevent complications that might follow an infection with varicella-zoster virus (VZV), the live attenuated Oka strain (V-Oka) is administered to children in many developed countries. Three vaccine brands (Varivax from Sanofi Pasteur MSD; Varilrix and Priorix-Tetra, both from Glaxo-Smith-Kline) are licensed in Germany and have been associated with both different degrees of vaccine effectiveness and adverse effects. To identify genetic variants in the vaccines that might contribute to rash-associated syndromes, single nucleotide polymorphism (SNP) profiles of variants from the three vaccines and rash-associated vaccine-type VZV from German vaccinees were quantitatively compared by PCR-based pyrosequencing (PSQ). The Varivax vaccine contained an estimated 3-fold higher diversity of VZV variants, with 20% more wild-type (wt) SNPs than Varilrix and Priorix-Tetra. These minor VZV variants in the vaccines were identified by analyzing cloned full-length open reading frame (ORF) orf62 sequences by chain termination sequencing and PSQ. Some of these sequences amplified from vaccine VZV were very similar or identical to those of the rash-associated vaccine-type VZV from vaccinees and were almost exclusively detected in Varivax. Therefore, minorities of rash-associated VZV variants are present in varicella vaccine formulations, and it can be concluded that the analysis of a core set of four SNPs is required as a minimum for a firm diagnostic differentiation of vaccine-type VZV from wt VZV.eng
dc.language.isoeng
dc.publisherRobert Koch-Institut, Infektionskrankheiten / Erreger
dc.subjectAnimalseng
dc.subjectHumanseng
dc.subjectChildeng
dc.subjectSequence Analysis DNAeng
dc.subjectDNA Viral/geneticseng
dc.subjectChickenpox Vaccine/adverse effectseng
dc.subjectExanthema/etiologyeng
dc.subjectExanthema/virologyeng
dc.subjectHerpesvirus 3 Human/geneticseng
dc.subjectPolymorphism Single Nucleotideeng
dc.subjectSkin Diseases/etiologyeng
dc.subjectSkin Diseases/virologyeng
dc.subject.ddc610 Medizin
dc.titleMolecular analysis of varicella vaccines and varicella-zoster virus from vaccine-related skin lesions.
dc.typeperiodicalPart
dc.identifier.urnurn:nbn:de:0257-10016184
dc.identifier.doi10.1128/​CVI.05021-11
dc.identifier.doihttp://dx.doi.org/10.25646/928
local.edoc.container-titleClinical and Vaccine Immunology
local.edoc.container-textThiele, S., Borschewski, A., Küchler, J., Bieberbach, M., Voigt, S., Ehlers, B. Molecular analysis of varicella vaccines and varicella-zoster virus from vaccine-related skin lesions (2011) Clinical and Vaccine Immunology, 18 (7), pp. 1058-1066.
local.edoc.fp-subtypeArtikel
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttp://cdli.asm.org/content/18/7/1058.abstract
local.edoc.container-publisher-nameAmerican Society for Microbiology
local.edoc.container-volume18
local.edoc.container-issue7
local.edoc.container-year2011

Zur Kurzanzeige